Rabbit anti-Human Synuclein, alpha Polyclonal Antibody | anti-SNCA antibody

Synuclein, alpha, CT (Non-A beta Component Of AD Amyloid, Non-A4 Component Of Amyloid Precursor, NACP, SNCA, PARK1) (MaxLight 490)

Cat. Num. AAA6501894

• Gene Names: SNCA; PD1; NACP; PARK1; PARK4
• Reactivity: Human
• Applications: Western Blot
• Purity: Purified by Ammonium Sulfate Precipitation.
• Synonyms: Synuclein; alpha; Polyclonal Antibody; CT (Non-A beta Component Of AD Amyloid; Non-A4 Component Of Amyloid Precursor; NACP; SNCA; PARK1) (MaxLight 490); anti-SNCA antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes human alpha Synuclein.
• Purity/Purification: Purified by Ammonium Sulfate Precipitation.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight490.

• Applicable Applications for anti-SNCA antibody: Western Blot (WB), FLISA
• Application Notes: WB: 1:100-1:500; FLISA: 1:1,000; Applications are based on unconjugated antibody.
• Immunogen: Synthetic peptide in the C-terminal region of human Alpha-synuclein that is specific for Alpha-synuclein isoform NACP140 not NACP112 (KLH).
• Conjugate: MaxLight490
• Note: Preservative Free
• Preparation and Storage: Store product at 4 degree C in the dark. DO NOT FREEZE! Stable at 4 degree C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight490 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Western Blot (WB)

(Western blot analysis of anti-Alpha-synuclein Pab in mouse brain tissue lysate. Alpha-synuclein (arrow) was detected using the purified Pab.)

Western Blot (WB)

(Western blot analysis of Park4 (arrow) using rabbit polyclonal Park4 Antibody (C-term). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the Park4 gene.)

Product Categories/Family for anti-SNCA antibody

Antibodies; Synuclein

References

1. Kumru, H., et al., Ann. Neurol. 56(4):599-603 (2004). 2. Pigullo, S., et al., Parkinsonism Relat. Disord. 10(6):357-362 (2004). 3. Yao, D., et al., Proc. Natl. Acad. Sci. USA 101(29):10810-10814 (2004). 4. West, A.B., et al., J. Biol. Chem. 279(28):28896-28902 (2004). 5. Wang, F., et al., Genes Chromosomes Cancer 40(2):85-96 (2004).

NCBI and Uniprot Product Information

• NCBI GI #: 4507109
• NCBI GeneID: 6622
• NCBI Accession #: NP_000336.1
• NCBI GenBank Nucleotide #: NM_000345.3
• UniProt Accession #: P37840; Q13701; Q4JHI3; Q6IAU6; A8K2A4
• Molecular Weight: 14,460 Da
• NCBI Official Full Name: alpha-synuclein isoform NACP140
• NCBI Official Synonym Full Names: synuclein, alpha (non A4 component of amyloid precursor)
• NCBI Official Symbol: SNCA
• NCBI Official Synonym Symbols: PD1; NACP; PARK1; PARK4
• NCBI Protein Information: alpha-synuclein; synuclein alpha-140; non A-beta component of AD amyloid
• UniProt Protein Name: Alpha-synuclein
• Protein Family: Alpha-synuclein
• UniProt Gene Name: SNCA
• UniProt Synonym Gene Names: NACP; PARK1; NACP
• UniProt Entry Name: SYUA_HUMAN

NCBI Description

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

Uniprot Description

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson's disease. A major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced isoforms transcripts have been identified.

Protein type: Adaptor/scaffold

Chromosomal Location of Human Ortholog: 4q21

Cellular Component: Golgi apparatus; nuclear outer membrane; rough endoplasmic reticulum; mitochondrion; lysosome; extracellular region; fibril; terminal button; cell cortex; inclusion body; cytosol; mitochondrial respiratory chain complex I; actin cytoskeleton; synaptic vesicle; platelet alpha granule membrane; growth cone; perinuclear region of cytoplasm; axon; cytoplasm; plasma membrane; ribosome; cell junction; nucleus

Molecular Function: protein domain specific binding; identical protein binding; histone binding; zinc ion binding; kinesin binding; microtubule binding; ferrous iron binding; caspase inhibitor activity; magnesium ion binding; beta-tubulin binding; phosphoprotein binding; protein N-terminus binding; oxidoreductase activity; Hsp70 protein binding; calcium ion binding; dynein binding; protein binding; phospholipase binding; copper ion binding; phospholipid binding; fatty acid binding; tau protein binding; alpha-tubulin binding

Biological Process: regulation of acyl-CoA biosynthetic process; adult locomotory behavior; positive regulation of apoptosis; positive regulation of endocytosis; response to lipopolysaccharide; dopamine biosynthetic process; positive regulation of neurotransmitter secretion; calcium ion homeostasis; response to magnesium ion; fibril organization and biogenesis; synapse organization and biogenesis; dopamine uptake; negative regulation of neuron apoptosis; response to drug; negative regulation of dopamine metabolic process; synaptic vesicle endocytosis; negative regulation of transporter activity; negative regulation of apoptosis; regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; mitochondrial membrane organization and biogenesis; negative regulation of norepinephrine uptake; microglial cell activation; negative regulation of transcription from RNA polymerase II promoter; negative regulation of caspase activity; negative regulation of monooxygenase activity; fatty acid metabolic process; regulation of dopamine secretion; negative regulation of dopamine uptake; negative regulation of histone acetylation; negative regulation of exocytosis; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; phospholipid metabolic process; receptor internalization; response to iron(II) ion; positive regulation of receptor recycling; aging; caspase activation; neutral lipid metabolic process; protein destabilization; regulation of macrophage activation; regulation of glutamate secretion; negative regulation of microtubule polymerization; positive regulation of peptidyl-serine phosphorylation; organelle ATP synthesis coupled electron transport; regulation of locomotion; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential

Disease: Parkinson Disease 4, Autosomal Dominant; Parkinson Disease 1, Autosomal Dominant; Dementia, Lewy Body